The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg). SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available. Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
